Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2002-05-24
2004-07-27
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424SDIG006, C514S184000, C514S299000, C514S305000, C514S424000, C514S428000, C514S502000, C514S579000, C514S604000, C514S764000, C514S769000, C514S970000, C514S973000
Reexamination Certificate
active
06767558
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to methods of inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and to pharmaceutical formulations comprising oxidation-inhibiting excipients.
The desirability of providing pharmaceutical formulations in which an oxidation-susceptible active drug ingredient or ingredients are protected against oxidative degradation inherent to prolonged storage is a concept well known to, and appreciated by, one of ordinary skill in the art. Anti-oxidants commonly employed in various pharmaceutical formulations may include, inter alia, vitamin E, ascorbic acid, BHT (butylated hydroxytoluene), BHA (butylated hydroxyanisole), and the like.
Pharmaceutical formulations comprising ferrous ion sources as nutritional supplements are generally well known in the art. The presence of ferrous ion sources in pharmaceutical formulations has additional utility in other capacities. For example, it has been reported that preservation of oral liquid preparations from bacterial contamination can be achieved by treatment with, inter alia, certain ferrous sulfate/methylparaben mixtures. See H. van Doorne, et al., Pharmacy World & Science, 16 (1), 18-21 (1994). It has also been reported that the addition of ferrous salts to compositions comprising acetylsalicylic acid, or salts thereof, reduces the propensity of the compositions to induce gastric irritation. See A. Goudie, et al., U.S. Pat. No. 4,083,951.
The present invention discloses methods for protecting an oxidation-susceptible active drug ingredient or ingredients in a pharmaceutical formulation from oxidative degradation which methods comprise adding a ferrous ion source to the formulation, preferably in the form of a pharmaceutical excipient comprising the formulation components. In this manner, pharmaceutical formulations are produced in which the active drug ingredient or ingredients are protected from oxidative degradation, thus facilitating storage of the formulation over extended periods of time.
SUMMARY OF THE INVENTION
The instant invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which comprises protecting the formulation by the addition of an oxidation-inhibiting amount of a ferrous ion source thereto, preferably in the form of a pharmaceutical excipient.
The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceutical excipient.
The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
REFERENCES:
patent: 4083951 (1978-04-01), Goudle et al.
patent: 5002779 (1991-03-01), Mehansho et al.
patent: 5817047 (1998-10-01), Osborn, III et al.
patent: 6013632 (2000-01-01), Jones et al.
The Merck Index, 12thed., Merck & Co., Inc., Whitehouse Station (NJ), 1996, pp. 686-687.*
H. van Doorne, et al., Pharmacy World & Science, vol. 16, No. 1, 1994, “The Preservation of Some Oral Liquid Preparations”.
Benson Gregg C.
O'Gorman Carmella A.
Pak John
Pfizer Inc.
Richardson Peter C.
LandOfFree
Inhibiting oxidative degradation of pharmaceutical formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting oxidative degradation of pharmaceutical formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting oxidative degradation of pharmaceutical formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3244109